Driving value in phase IIIb & IV trials
 |
 
|
Overview
Late Phase Drug Development World Europe helps you address the various challenges of collecting data on clinical and quality of life outcomes and economic value under real-world conditions. Get the answers you need to overcome the challenges you face on a daily basis.
Learn how to gain a competitive edge in the market.
Who's speaking?
- Dr Robert Maykut, Novartis
- Aodan Tynana, GSK
- Dr Agnes Rivaille, PRA
- Dr Marc Adamy, Roche
- Dr Jens Dollerup, Pfizer
- Dr Marie Aavang Geist, Lundbeck
- Tanja Hultsch, Optum
- Dr Jean-Marc C. Haeusler, UCB
Download a brochure for a more detailed breakdown of who is attending and more in-depth information about the presentations:
What will you learn?
- How to get to grips with presenting real-world data to maximise value to regulators and payers
- How to manage the evidence to support product claims and expand into further indications
- How to tackle the challenges of post-approval safety surveillance in the new EU environment
- How to make post approval studies in unique patient groups and product classes
- How to validate your approach to assessing therapeutics in regulatory-mandated studies
Who's speaking?
Marc joined Roche in 1998 as a Strategic Planning Manager. In this role, he developed a portfolio overview and a 5 year projection including various risk parameters inherent to our industry. In 2004, Marc joined Project Management as a Global Project Manager supporting …more ›
Marc AdamySenior Quality Leader Roche
Fredrik L Andersson is a Senior Director, Health Economics & Outcomes Research (HEOR) at Ferring Pharmaceuticals, based in Copenhagen, Denmark. Fredrik graduated as BSc in Computer Sciences and later completed a PhD in Health Economics at the University of Linkö…more ›
Fredrik L AnderssonSenior Director Health Economics Ferring Pharmaceuticals
Dr Peter Boyle,
BSc PhD DSc(Med) DSc FRSE FFPH FRCPS(Glas) FRCP(Edin) FMedSci
Dr Boyle’s appointment as President of the International Prevention Research Institute, Lyon, France follows immediately on his tenure as Director of the International Agency for Research on C…more ›
Peter BoylePresident International Prevention Research Institute
Dr Chris Bushe
Qualified in 1981 St Georges Med School London. Initially worked in acute medical specialities and ITU and then entered the pharmaceutical industry involved mainly with thrombolytics for myocardial infarction. Having decided that I remained too young and…more ›
Chris J BusheSenior Medical Advisor Eli Lilly
Holds a MSc/PhD from the university of Copenhagen in Biology/Zoology. Working in the pharmaceutical industry since 1984 (Merck & Co. and Pfizer)
More than 30 pear reviewed publications and numerous presentations at major international congresses within the areas of …more ›
Jens DollerupSenior Medical Scientist GlaxoSmithKline
Marc joined Roche in 1998 as a Strategic Planning Manager. In this role, he developed a portfolio overview and a 5 year projection including various risk parameters inherent to our industry. In 2004, Marc joined Project Management as a Global Project Manager supporting …more ›
Fredrik L Andersson is a Senior Director, Health Economics & Outcomes Research (HEOR) at Ferring Pharmaceuticals, based in Copenhagen, Denmark. Fredrik graduated as BSc in Computer Sciences and later completed a PhD in Health Economics at the University of Linkö…more ›
Dr Peter Boyle, BSc PhD DSc(Med) DSc FRSE FFPH FRCPS(Glas) FRCP(Edin) FMedSci Dr Boyle’s appointment as President of the International Prevention Research Institute, Lyon, France follows immediately on his tenure as Director of the International Agency for Research on C…more ›
Dr Chris Bushe Qualified in 1981 St Georges Med School London. Initially worked in acute medical specialities and ITU and then entered the pharmaceutical industry involved mainly with thrombolytics for myocardial infarction. Having decided that I remained too young and…more ›
Holds a MSc/PhD from the university of Copenhagen in Biology/Zoology. Working in the pharmaceutical industry since 1984 (Merck & Co. and Pfizer) More than 30 pear reviewed publications and numerous presentations at major international congresses within the areas of …more ›
